日本語⁄English
2019.06.04
【NanoCarrier Co.,Ltd.】「Press release by VBL Therapeutics on “Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity”」
